美国食品药品监督管理局动力粉碎咨询后子宫切除术式趋势
本研究回顾性分析了2013至2015年布莱根妇女医院因良性指征、特别是子宫肌瘤行子宫切除术的患者,比较腹部、阴道、腹腔镜及机器人辅助腹腔镜子宫切除术的比例及围手术期结局。结果显示,与2013年相比,2014年和2015年微创手术的调整比值比分别为0.53(0.29-0.97)和0.40(0.22-0.74),呈下降趋势,但每年多数病例仍为微创方式,且围手术期结局无显著差异。
要点
- 2013至2015年因良性指征行子宫切除术共1530例,其中因子宫肌瘤手术639例,后几年手术例数减少。
- 仅针对子宫肌瘤患者,2014年和2015年微创手术的调整OR分别为0.53(0.29-0.97)和0.40(0.22-0.74),P=.003。
- 每年多数病例仍为微创方式,且手术年份与术中并发症或再手术无显著差异。
核心结论
- 尽管关键围手术期结局相似,但美国食品药品监督管理局(FDA)建议后,本机构微创手术总体比例下降。
- 随着实践模式变化和对动力粉碎的警惕,妇科医生仍可为患者提供微创手术及其伴随优势。
研究设计与样本
- 回顾性综述,纳入2013至2015年在布莱根妇女医院因良性指征(特别是子宫肌瘤)行子宫切除术的所有患者。
- 比较腹部、阴道、腹腔镜及机器人辅助腹腔镜子宫切除术的比例及围手术期结局,采用多变量线性、多项式和逻辑回归分析,并调整潜在混杂因素。
主要发现
- 2013至2015年,因良性指征行子宫切除术1530例,因子宫肌瘤手术639例,后几年子宫切除术例数减少。
- 仅针对子宫肌瘤患者,与2013年相比,2014年微创手术的调整OR为0.53(0.29-0.97),2015年为0.40(0.22-0.74),P=.003。
- 子宫颈上子宫切除术式减少24%。
- 每年多数病例仍以微创方式完成。
- 与微创子宫切除术最强相关的因素是手术由接受过专科培训的医生施行,调整OR为6.80(3.65-12.7),P<.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the trends in mode of surgery for benign hysterectomy after the 2014 U.S. Food and Drug Administration (FDA) morcellation guidelines. METHODS: This is a retrospective review of all patients who underwent a hysterectomy for benign indications, specifically for leiomyomas, at Brigham and Women's Hospital from 2013 to 2015. The rates of abdominal, vaginal, laparoscopic, and robotic-assisted laparoscopic hysterectomy as well as the perioperative outcomes were compared over the study period. Analysis was performed using multivariable linear, multinomial, and logistic regression. Regression models were adjusted for potential confounders. RESULTS: From 2013 to 2015, 1,530 patients underwent a hysterectomy for benign indications and 639 patients underwent the procedure for the indication of uterine leiomyomas; there was a decrease in the number of hysterectomy cases in the later years. Focusing on the patients with leiomyomas alone, there was a 40-60% decreased odds of a minimally invasive procedure in 2014 or 2015 compared with 2013 [adjusted odds ratio (OR) 0.53 (0.29-0.97) in 2014 and adjusted OR 0.40 (0.22-0.74) in 2015, P=.003]. A 24% decrease in the supracervical approach to hysterectomy was also noted. Despite these trends, the majority of cases in each year were still performed in a minimally invasive fashion. The factor most strongly associated with undergoing a minimally invasive hysterectomy was having a fellowship-trained surgeon perform the procedure [adjusted OR 6.80 (3.65-12.7), P<.001]. There was no significant difference between the year of surgery and occurrence of intraoperative complications or reoperation. CONCLUSION: Although key perioperative outcomes remained similar, the overall rate of minimally invasive surgery declined at our institution after the FDA's recommendations. With changing practice patterns and vigilance surrounding power morcellation, gynecologic surgeons may still offer patients minimally invasive procedures with all of the accompanying advantages.
引用
- Ottarsdottir H, Cohen SL, Cox M, et al. Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory. Obstet Gynecol. 2017. PMID: 28486371. doi:10.1097/AOG.0000000000002058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。